Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Acute and late disease induced by murine coronavirus, strain JHM, in a series of recombinant inbred strains between BALB/cHeA and STS/A mice

Shigeru Kyuwa,¹ Kenjiro Yamaguchi,¹ Yutaka Toyoda,¹ Kosaku Fujiwara² and Jo Hilgers³

¹Department of Animal Pathology, Institute of Medical Science, University of Tokyo, 4-6-l Shirokanedai, Minato-ku, Tokyo 108, Japan, ²Laboratory of Pathobiology, Nihon University School of Veterinary Medicine, Fujisawa 252, Japan and ³Department of Obstetrics and Gynaecology, Academisch Ziekenhuis Vrije Universiteit, 1081 HV Amsterdam, The Netherlands

(Received May 23, 1991; accepted in revised form September 30, 1991)

Kyuwa, S. (Dept of Animal Pathology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan), K. Yamaguchi, Y. Toyoda, K. Fujiwara and J. Hilgers. Acute and late disease induced by murine coronavirus, strain JHM, in a series of recombinant inbred strains between BALB/cHeA and STS/A mice. Microbial Pathogenesis 1992; 12: 95-104.

To examine the genetic control of acute and late disease induced by a murine coronavirus, strain JHM (JHMV), BALB/cHeA, STS/A, F₁ hybrids and 13 recombinant inbred (RI) strains between BALB/cHeA and STS/A mouse strains were inoculated intracerebrally with 100 pfu of JHMV. All the BALB/cHeA mice died within 2 weeks from acute encephalitis. In contrast, STS/A mice were shown to be partially resistant, with a mortality rate of 30%, longer survival times and lower rates of viral production. The mortality rates, survival times and viral titers of F₁ hybrids and the RI strains varied, suggesting involvement of multiple genes. STS/A, F₁ hybrid and RI mice surviving the acute infection occasionally developed severe paraparesis about 1 month post-infection. In these mice, vacuolar degeneration, astrocytosis, the absence of perivascular cuffing and minimal demyelination were found in the central nervous system. No infectious virus could be recovered from these mice. Although the paralysis of delayed onset was limited to STS/A, F₁ hybrid and eight of the 13 RI strains, the incidence varied significantly among the RI strains. These results may suggest that JHMV-induced late disease is also under multifactorial control. The pathogenesis of JHMV infection is discussed.

Key words: central nervous system; coronavirus; fatal encephalitis; genetic control; paralysis.

Introduction

Murine coronavirus infections induce a variety of diseases in mice.¹ A number of informative studies using prototype viruses, including the JHM strain (JHMV),² have been reported. Similar to other viral infections, the fate and the process of primary coronavirus infection in mice are dependent on genetic factors of both host and virus. For instance, almost all the laboratory strains of mice except for SJL/J mice die after intracerebral (i.c.) infection with JHMV, due to acute encephalomyelitis.³,⁴ A comparative study between JHMV-susceptible BALB/c and JHMV-resistant SJL/J mice indicated that susceptibility expressed in neuronal cells as well as macrophages was controlled by a single dominant gene.⁴ Furthermore, the locus was linked to the...
Svp-2 locus on the proximal end of mouse chromosome 7, using recombinant inbred (RI) strains between susceptible SWR/J and resistant SJL/J strains. However, the resistance to acute JHMV infection may involve another gene, which probably regulates the immune response to JHMV.

Mice surviving the acute phase of JHMV infection occasionally develop paralysis with demyelination in the central nervous system. This disease has been studied as an animal model of human demyelinating diseases such as multiple sclerosis. In contrast to the acute fatal infection, little is known about the host genetic factor(s) which control JHMV-induced paralysis with delayed onset. However, it is very important to clarify the role(s) of the factors because they may hold a key to understanding the pathogenesis of paralytic disease induced by this neurotropic virus.

On the other hand, viral genetic factors indubitably influence JHMV infection in mice. Although the wild-type virus induces acute fatal encephalomyelitis in mice, some mutants and variants of JHMV with different pathogenicities have been reported. Temperature sensitive mutants, plaque size mutants and variants selected by resistance to neutralizing monoclonal antibodies (mAbs) induce demyelination but not fatal encephalomyelitis. One variant, designated JHM-cc, isolated from DBT cells persistently infected with JHM-x, induces vacuolar degeneration.

We attempted to analyse the genetic control of the acute and late diseases after infection with a low dose of JHMV using BALB/cHeA, STS/A, F₁ hybrid and 13 RI strains between BALB/cHeA and STS/A mouse strains, since the two parent strains of mice show different pathogenesis after i.c. infection.

Results

JHMV-induced acute disease
Female, 6–8-week-old mice of BALB/cHeA, STS/A, F₁ hybrid and RI strains were inoculated i.c. with 100 pfu of JHMV and monitored for acute disease for 2 weeks. A total of 588 mice were used in 21 experiments. The cumulative results of these experiments are summarized in Table 1. After i.c. infection with 100 pfu of JHMV, all mice showed signs of mild or severe encephalitis. Following the onset of the clinical signs, 100% of the BALB/cHeA mice and 30% of the STS/A mice died within 2 weeks. Both F₁ hybrids (BALB/cHeA × STS/A)F₁ (CSF₁) and (STS/A × BALB/cHeA)F₁ (SCF₁) died with intermediate rates during the acute phase. The mortality of the RI strains varied from 72–100%. Interestingly, two RI strains (CXS6 and CXS14) exhibited high mortality similar to the BALB/cHeA parental strain. STS/A mice were also less susceptible than BALB/cHeA mice with respect to survival times.

Virus titers in the brains from all strains were assayed on day 5 post-infection (p.i.), when virus titer peaks in both BALB/cHeA and STS/A mice. Although the difference in viral titers was limited among the strains tested, a lower rate of viral growth was observed in STS/A mice compared to BALB/cHeA mice. There was a slight positive correlation between the mortality and the viral titer (r = 0.42). There was also a slight negative correlation between survival times and the viral titers (r = 0.53).

Two each of BALB/cHeA, STS/A and both F₁ hybrid mice were sacrificed on day 5 p.i. for histological examinations. Immunoperoxidase staining revealed abundant viral antigens in the brains and spinal cords of BALB/cHeA mice [Fig. 1(a)]. In STS/A mice, less viral antigens were detected; however, the inflammatory response, especially perivascular cuffing, was more prominent than BALB/cHeA mice [Fig. 1(b)].

JHMV-induced late disease
The animals that survived acute infection were monitored for late disease till 2 months p.i. (Table 2). All of the STS/A mice that had survived acute infection recovered.
Table 1 Summary of acute JHMV infection in BALB/cHeA, STS/A, F₁ hybrid and CXS RI mice

| Mouse         | Mortalityᵃ (no. dead/no. tested) (%) | Survival timeᵇ (day) | Virus titerᶜ (log pfu/g) |
|---------------|-------------------------------------|----------------------|-------------------------|
| BALB/cHeA     | 29/29                               | 100                  | 5.7 ± 1.1               | 6.7 ± 0.1               |
| STS/A         | 6/20                                | 30                   | 9.3 ± 1.6               | 5.7 ± 0.1               |
| CSF₁          | 20/32                               | 63                   | 8.8 ± 1.7               | 6.1 ± 0.1               |
| SCF₁          | 7/10                                | 70                   | 9.4 ± 1.4               | NT³                    |
| CXS1          | 45/50                               | 90                   | 7.1 ± 1.4               | 6.5 ± 0.2               |
| CXS2          | 32/41                               | 78                   | 9.5 ± 1.7               | 6.2 ± 0.3               |
| CXS3          | 36/38                               | 95                   | 8.1 ± 1.5               | 5.7 ± 0.1               |
| CXS4          | 9/10                                | 90                   | 5.7 ± 0.9               | NT                     |
| CXS5          | 49/61                               | 80                   | 6.7 ± 2.2               | 6.1 ± 0.1               |
| CXS6          | 30/30                               | 100                  | 8.2 ± 2.1               | NT                     |
| CXS7          | 42/47                               | 89                   | 7.9 ± 1.6               | 6.1 ± 0.8               |
| CXS8          | 14/16                               | 88                   | 7.7 ± 1.3               | 6.5 ± 0.3               |
| CXS10         | 26/34                               | 76                   | 8.7 ± 1.6               | 6.2 ± 0.1               |
| CXS11         | 50/68                               | 74                   | 8.5 ± 1.3               | 6.1 ± 0.1               |
| CXS12         | 32/41                               | 78                   | 8.8 ± 1.7               | 6.6 ± 0.4               |
| CXS13         | 21/29                               | 72                   | 8.4 ± 1.2               | 6.4 ± 0.1               |
| CXS14         | 32/32                               | 100                  | 6.5 ± 1.1               | 6.1 ± 0.4               |

ᵃ Mortality was determined at 2 weeks p.i.
ᵇ Mean survival days ± SD of dead mice.
ᶜ Mean virus titer of the brains ± SD from 3 mice at day 5 p.i.
³ NT: Not tested.

Clinically by 3 or 4 weeks p.i. Subsequently, one-third of the STS/A survivors began to show severe hind leg paralysis beginning about 1 month p.i., and then died by 2 months p.i. Some of the F₁ hybrids and of some RI strains (CXS2, CXS3, CXS4, CXS5, CXS8, CXS11, CXS12 and CXS13) also showed hind leg paralysis. However, the incidence of paralysis varied greatly among the RI strains (8–100%). In addition, some mice recovered from the paralysis, in contrast to the parent STS/A mice. Mice of CXS1, CXS7 and CXS10 strains showed no evidence of paralysis. Some mice which were clinically normal during the initial 2 months were monitored for an extended period.

Fig. 1. Acute JHMV infection in the brains after i.c. inoculation with 100 pfu of JHMV. (a) Acute necrotic panencephalitis in BALB/cHeA mouse. Note abundant viral antigen in neurons and glia, and nucleus caudatus. 5 days post-infection. Immunoperoxidase staining ×105. (b) Perivascular cuffing observed in the cerebrum of STS/A mouse. 5 days post-infection. Hematoxylin and eosin ×420.
Table 2  Summary of subacute JHMV disease in BALB/cHeA, STS/A, F1 hybrid and CXS RI mice

| Mouse       | No. observed | No. paralysed | (%) | No. dead | Mean day of death |
|-------------|--------------|---------------|-----|----------|-------------------|
| BALB/cHeA   |              |               |     |          |                   |
| STS/A       | 14           | 5             | 36  | 5        | 47.2              |
| CSF1        | 12           | 4             | 33  | 4        | 33.8              |
| SCF1        | 3            | 2             | 67  | 2        | 36.5              |
| CXS1        | 5            | 0             | 0   | 0        | -                 |
| CXS2        | 9            | 1             | 11  | 0        | -                 |
| CXS3        | 2            | 1             | 50  | 0        | -                 |
| CXS4        | 1            | 1             | 1   | 1        | 26.0              |
| CXS5        | 12           | 1             | 8   | 0        | -                 |
| CXS6        |              |               |     |          |                   |
| CXS7        | 5            | 0             | 0   | 0        | -                 |
| CXS8        | 2            | 7             | 100 | 7        | 31.0              |
| CXS10       | 8            | 0             | 0   | 0        | -                 |
| CXS11       | 18           | 7             | 39  | 2        | 31.5              |
| CXS12       | 9            | 3             | 33  | 0        | -                 |
| CXS13       | 8            | 6             | 75  | b        | 34.4              |
| CXS14       |              |               |     |          |                   |

* Mice surviving acute infection were monitored from 2 weeks to 2 months p.i.

Table 3  Summary of virus isolation from the brains of infected mice

| No. | Days p.i. | Strain | Clinical sign | CPE |
|-----|-----------|--------|---------------|-----|
| 1   | 11        | CXS2   | E             | +   |
| 2   | 11        | CSF1   | E             | +   |
| 3   | 19        | CXS7   | E             | -   |
| 4   | 38        | CXS11  | P             | -   |
| 5   | 45        | CXS12  | P             | -   |
| 6   | 61        | STS/A  | None          | -   |
| 7   | 61        | CXS2   | P → None      | -   |
| 8   | 61        | CXS3   | P → None      | -   |
| 9   | 61        | CXS7   | None          | -   |
| 10  | 61        | CXS11  | None          | -   |
| 11  | 61        | CXS11  | None          | -   |
| 12  | 78        | CXS11  | P             | -   |
| 13  | 78        | CXS11  | P → None      | -   |
| 14  | 115       | CXS11  | P             | -   |
| 15  | 115       | CXS11  | P             | -   |

*E, encephalitis; P, paralysis; P → None, healthy mice which have been recovered from paralysis.

*10% homogenates of brains were inoculated on DBT cells. CPE was observed carefully by 48 h p.i.
Acute and late disease induced by murine coronavirus

Fig. 2. Histopathological changes in brains of paralysed STS/A mice following i.c. inoculation with 100 pfu of JHMV. (a) Marked vacuolar degeneration in the pons. 50 days post-infection. Hematoxylin and eosin ×159. (b) Involvement of astrocytosis in vacuolar degeneration. 50 days post-infection. Immunoperoxidase staining ×159.

[Fig. 2(a)]. Astrocytosis was also observed in the lesions [Fig. 2(b)]. However, there was little infiltration by mononuclear cells. Trace amounts of viral antigens were detected. The degree of demyelination also appeared to be slight. Although the number of samples was limited, no obvious difference in the histopathological changes dependent on mouse strain was observed in mice manifesting paralysis. These histological changes appeared to be distinct from that of mice infected with a JHMV variant (2.2-V-1) with a major demyelination inducing determinant.15,16

Discussion

Several strains of murine coronavirus have facilitated studies of natural resistance to viral infections. Bang et al. found that a single recessive gene encodes the resistance of PRI mice to mouse hepatitis virus type 2 infection.17 Alternatively, a genetic study indicated that resistance to mouse hepatitis virus type 3 infection involves at least two major genes: one for the acute disease and the other, H-2-linked, for the chronic disease.18 The genetic resistance to JHMV infection has also been studied by several groups but remains controversial. Stohlman et al. found that only SJL/J mice are resistant to acute fatal JHMV infection among 19 strains tested3,19 and suggest that two genes are involved in the resistance to acute fatal JHMV infection.3 However, using a lower dose of virus, Knobler et al. suggest that a single gene controls the resistance to acute JHMV infection in SJL/J mice.4 Furthermore, the mechanism of the resistance seems to be discrepant. Although Wilson and Dales find no critical difference in the early events from adsorption to genome activation between JHMV-resistant SJL/J and JHMV-susceptible CD.1 glial cultures,20 Holmes and colleagues have proposed that the resistance of SJL/J mice is perhaps due to the lack of functional virus receptor on the plasma membrane.21

To examine the genetic control of diseases induce by the JHMV strain maintained in this laboratory, some preliminary experiments were performed. As reported earlier,3,4 BALB/cHeA, C57BL/6, C57BL/10 and DBA/2 mice died due to acute encephalitis after i.c. infection with 100 pfu of JHMV. However, 30% of STS/A and 100% of SJL/J mice survived the acute phase of infection. In addition, some survivors of the STS/A strain subsequently manifested hind leg paralysis (data not shown). Due to the
availability of RI strains between the BALB/cHeA and STS/A strains, we chose these parent strains to carry out genetic analysis of JHMV-induced disease. Compared to BALB/cHeA mice, STS/A mice exhibited lower mortality rates, longer survival times and lower virus titers in the brains during acute infection. However, STS/A mice might be classified as semi-resistant for JHMV infection because no SJL/J mice died after i.c. inoculation with the same dose of JHMV (data not shown). This suggests that the mechanism of the resistance of STS/A mice is not identical with that of SJL/J mice. Histopathological changes may suggest some possible mechanisms of resistance. The paucity of viral antigens in STS/A mice may suggest that the difference in susceptibility is expressed in neuronal cells where virus replicates. The perivascular cuffing observed in STS/A mice may also suggest the involvement of the immune system in the resistance.

Unlike the inheritance of the resistance of SJL/J mice, the genetic basis of the resistance of STS/A mice may be complicated. Both CSF1 and SCF1 hybrids, as well as almost all the RI strains, showed intermediate values for mortality rates, survival times and virus titers in the brain. These data suggest that the resistance is a multiple trait and not due to one major gene effect in this combination of mouse strains. The hypothesis is consistent with the multiple differences of histopathological changes between STS/A and BALB/cHeA mice during the acute phase.

A recent study indicated that a mutant JHMV designated JHM-cc induced paralysis associated with vacuolar degeneration but not demyelination, although demyelination has generally been ascribed as the cause of paralysis following murine coronavirus infections in the central nervous system of mice. The late disease observed in this study largely agrees with these results. The virus used in this study does not have a major demyelination-inducing determinant characterized by mAb J.7.2. Similarly, JHM-cc virus probably lacks the determinant because it is derived from the virus used in this study. Furthermore, murine coronavirus strain A59, which also induces vacuolar degeneration in the spinal cord, did not react with this mAb. These data suggest that some genetic factor of virus affects paralysis with vacuolar degeneration. One possibility is the deletions in the S gene found among these virus strains. However, some secondary response(s) to the viral component rather than viral cytopathic effect may be responsible for the vacuolar degeneration, since it does not coincide with viral replication.

Vacuolar degeneration in the central nervous system is not unique in coronavirus infections, but is also observed in other virus infections, poisoning and metabolic defects, and is often associated with astrogliosis. Furthermore, there has been accumulating evidence which accords prominence to the role of astrocytes in neurodegenerative diseases such as scrapie and Alzheimer’s. Although only traces of viral antigen were detected in the lesions of paralysed mice in this study, Perlman and Ries suggested that astrocyte is a potential target cell in which JHMV establishes a latent or low level persistent infection. Therefore, it may be important to know what happens during the process of recovery from acute encephalitis in those mice doomed to paralysis, especially interaction between virus and astrocyte.

In the genetic study of late disease, F1 hybrid mice exhibited paralysis with almost the same incidence (40%) as STS/A mice (36%). This suggests that the paralytic disease induced by this virus may be inherited as a dominant trait. Although the number of mice tested was not large enough to make this conclusion, the large variation in the incidence of paralysis among RI strains might suggest that paralytic disease is also inherited as a multiple trait.

Our data suggest that JHMV-induced acute and late disease is inherited as a multiple trait. Nonetheless, differential incidence of gene expression, possibly due to
environmental influences and variable penetrance of the gene, cannot be ruled out. Therefore, it may be worth analysing the genetics of JHMV-induced disease using the hypothesis that a single gene, or one major gene, controls the disease. We have tentatively designated the gene as Pj-1 and divided the mouse strains into the strains showing sublethal infection with paralysis of delayed onset, represented by STS/A mice, and the strains inducing fatal encephalitis, represented by BALB/cHeA mice. Mice exhibiting more than a 30% incidence were considered to constitute a STS/A type strain. The mouse strain which died from acute encephalitis was considered to constitute a BALB/cHeA type. Comparing with the strain distribution pattern (SDP) of 92 genes which have determined thus far, we found a good correlation between the SDP of the Pj-1 and the SDP of some markers on mouse chromosome 7 (Table 4). Since no recombinant was observed between the Pj-1 and Ly-15, the Pj-1 gene may be located near the Ly-15 locus. The Ly-15 encodes one of immunologically important molecules known as lymphocyte function-associated antigen-1 (LFA-1). LFA-1 is believed to bind to ICAM-1 and facilitate T cell recognition. In fact, Davignon et al. have shown that this molecule is involved in cytotoxic T cell response, which is believed to be a major effector mechanism in JHMV clearance from the brain. Since infection of neurons resulting in a necrotizing fatal encephalomyelitis is a major cause of death due to JHMV infection, it is possible that this molecule is involved, not only in the prevention of death by limiting virus replication, but also in the development of late disease.

Finally, STS/A mice was semi-resistant to JHMV and showed a biphasic CNS disease following JHMV infection. The same phenomenon was reported in mouse hepatitis type 3 infection. Semi-susceptibility of the host seems to be necessary for the development of late disease. This may suggest that host’s antiviral response(s) not only protect mice from a necrotizing encephalitis but also trigger late disease. Alternatively, increased incidence of late disease was observed following transfer of partial immunity to JHMV. Taken together, JHMV-induced late disease may occur under a subtle balance between the virus and the immune system. Polygenic inheritance may be suitable to interpret such a complex situation.

Materials and methods

Mice. BALB/cHeA, STS/A, CSF1, SCF1, and 13 RI strains between BALB/cHeA and STS/A were bred and maintained in our laboratory. The breeding colonies were kept in a lamina flow-

| Locus | CXS |
|-------|-----|
| Mpt-1 | S S S S S S C C S S S S |
| Gpi-1 | S S S S S S C C S S S S |
| Prt-4,5 | S S S S S C C S S S S |
| Pj-1  | C C S S S S C C S S S S |
| Ly-15 | C C S S S S C C S S S S |

The symbols C and S indicate the alleles inherited from BALB/cHeA and STS/A mice, respectively. (—) Indicates not to be unclassified; ( ) indicates not to be determined. Gene loci are aligned from the centromere to the telomere. × Denotes a region of recombination.
ventilated rack system and were routinely checked serologically for the absence of murine hepatitis virus (MHV). Female, 6–8-week-old mice were used throughout the experiments.

**Virus.** JHMV was propagated and plaque assayed on DBT cells as described previously. A single pool of virus was divided into aliquots and stored at −70°C until use. The virus used in this study does not have virus neutralizing determinants characterized by mAbs J.7.2 and J.2.2 (data not shown). Mice were inoculated i.c. with 100 pfu of JHMV in a volume of 0.02 ml.

**Titration and isolation of infectious virus.** To determine the virus titer, brains were removed aseptically. Ten per cent homogenates of the brains were made in chilled Eagle’s minimum essential medium (MEM). After centrifugation at 600 × g for 10 min, 0.2 ml of serial 10-fold dilutions of the supernatants was inoculated on monolayers of DBT cells in duplicate. After adsorption for 60 min, cultures were overlaid with MEM containing 1.5% pre-screened newborn calf serum, 5% tryptose phosphate broth and 0.8% agar. After incubation for 2 days at 37°C, plaques were visualized with neutral red. For virus isolation, the supernatants of 10% homogenates were inoculated on monolayers of DBT cells in 60 mm dishes. After adsorption for 60 min, cultures were washed once and then fed with 5 ml of MEM supplemented with 1.5% newborn calf serum and 5% tryptose phosphate broth. Cytopathic effect was carefully checked visually under microscope after 48 h.

**Clinical observation.** The clinical status of infected mice was assessed by the methods of Fleming et al. Briefly, mice were considered normal if they appeared alert and could turn over within 2 s after being placed on their back. Mice that had a waddling gait and were unable to rapidly turn over were scored as having mild paralysis. Mice with frank hind leg immobility were scored as having severe paralysis. Animals with hyperirritability or myoclonus were judged to have mild encephalitic signs. Seizure, persistent turning or static, hunched posture were considered to be signs of severe encephalitis.

**Histology.** The brains and spinal cords were embedded in paraffin and stained with hematoxylin and eosin, and luxol fast blue as previously described. Sections were stained by an avidin-biotin immunoperoxidase procedure using mAb to the JHMV N protein and anti-glial fibrillary acidic protein antibody (Paesel, Frankfurt).

**Statistics.** Coefficient of correlation was calculated by a scientific calculator (Casio, Tokyo) by the following formula:

\[
r = \frac{n \sum xy - \sum x \sum y}{\sqrt{[n \sum x^2 - (\sum x)^2] [n \sum y^2 - (\sum y)^2]}}^{1/2}
\]

We are grateful to Stephen A. Stohlman for his critical review of the manuscript. We are also grateful to John O. Fleming for a gift of monoclonal antibodies and to Yutaka Matsubara for excellent technical assistance.

**References**

1. Wege H, Siddel S, ter Meulen V. The biology and pathogenesis of coronaviruses. Curr Top Microbiol Immunol 1982; 99: 165–200.
2. Cheever FS, Daniels JB, Pappenheimer AM, Bailey OT. A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. I. Isolation and biological properties of the virus. J Exp Med 1949; 90: 181–94.
3. Stohlman SA, Frelinger JA. Resistance to fatal central nervous system disease by mouse hepatitis virus, strain JHM. I. Genetic analysis. Immunogenetics 1978; 6: 277–81.
4. Knobler RL, Haspel MV, Oldstone MBA. Mouse hepatitis virus type 4 (JHM strain)-induced fatal central nervous system disease. I. Genetic control and the murine neuron as the susceptible site of disease. J Exp Med 1981; 153: 832–43.
5. Knobler RL, Taylor BA, Wooddell MK, Deamer WG, Oldstone MBA. Host genetic control of mouse hepatitis virus type-4 (JHM strain) replication. II. The gene locus for susceptibility is linked to the Svp-2 locus on mouse chromosome 7. Exp Clin Immunogen 1984; 1: 217–22.
6. Kyuwa S, Stohlman SA. Pathogenesis of a neurotropic murine coronavirus, strain JHM in the central nervous system of mice. Semin Virol 1990; 1: 273–80.
7. Haspel MV, Lampert PW, Oldstone MBA. Temperature-sensitive mutants of mouse hepatitis virus produce a high incidence of demyelination. Proc Natl Acad Sci USA 1978; 75: 4033–6.
Acute and late disease induced by murine coronavirus

8. Erlich SS, Fleming JO, Stohlman SA, Weiner LP. Experimental neuropathology of chronic demyelination induced by a JHM virus variant (DS). Arch Neurol 1987; 44: 839-42.

9. Goto N, Tsutsuji Y, Sato A, Fujimura K. Neuropathogenicity of mutant strains of mouse hepatitis virus, JHM, Jpn J Vet Sci 1987; 49: 779-86.

10. Fleming JO, Trousdale MD, El-Zaatri FAK, Stohlman SA, Weiner LP. Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. J Virol 1986; 58: 869-75.

11. Dalziel RG, Lampert PW, Talbot PJ, Buchmeier MJ. Site specific alteration of murine hepatitis virus type-4 (MHV-4) peplomer glycoprotein E2 results in reduced neurovirulence. J Virol 1986; 59: 463-71.

12. Hirano N, Goto N, Makino S, Fujiwara K. Persistent infection with mouse hepatitis virus, JHM strain in DBT cell culture. In: ter Meulen V, Siddell S, Wege H, eds. The biochemistry and biology of coronaviruses. New York: Plenum Press, 1981; 301-8.

13. Tsukamoto T, Hirano N, Iwasaki Y, Haga S, Terunuma H, Yamamoto T. Vacuolar degeneration in mice infected with a coronavirus JHM-cc strain. Neurology 1990; 40: 904-10.

14. Hilgers J, Arens J. A series of recombinant inbred strains between the BALB/cHeA and STS/A mouse strains. Curr Top Microbiol Immunol 1985; 122: 31-7.

15. Fleming JO, Trousdale MD, Bradbury J, Stohlman SA, Weiner LP. Experimental demyelination induced by coronavirus JHM (MHV-4): molecular identification of a viral determinant of paralytic disease. Microb Pathogen 1987; 3: 9-20.

16. Wang FL, Stohlman SA, Fleming JO. Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated. J Neuroimmunol 1990; 30: 31-41.

17. Bang F, Warwick AX. Mouse macrophages as host cells for the mouse hepatitis virus and the genetic basis of their susceptibility. Proc Natl Acad Sci USA 1980; 46: 1065-75.

18. Levy-LeBled E, Oth D, Dupuy JM. Genetic study of mouse sensitivity to MHV3 infection: influence of the H-2 complex. J Immunol 1979; 123: 1359-62.

19. Stohlman SA, Knobel RL, Frelinger JA. Genetic control of resistance to lethal coronavirus strain JHM encephalitis. In: E Skamene, ed. Genetic control of host resistance to infection and malignancy. New York: Alan R Liss, 1985; 125-33.

20. Wilson GAR, Dalee S. In vivo and in vitro models of demyelinating disease: efficiency of virus spread and formation of infectious centers among glial cells is genetically determined by the murine host. J Virol 1988; 62: 3371-7.

21. Williams RK, Jiang GS, Snyder SW, Frana MF, Holmes KV. Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A59 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice. J Virol 1990; 64: 3817-23.

22. Lavi E, Gilden DH, Wroblewska Z, Rorke LB, Weiss SR. Experimental demyelination produced by the A59 strain of mouse hepatitis virus. Neurology 1984; 34: 597-603.

23. Fleming JO, Stohlman SA, Harmon RC, Lai MMC, Frelinger JA, Weiner LP. Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus. Viology 1983; 131: 296-307.

24. Banner LR, Keck JG, Lai MMC. A clustering of RNA recombination sites adjacent to a hypervariable region of the peplomer gene of murine coronavirus. Viology 1990; 175: 548-55.

25. Sharer LR, Cho ES. Neuropathology of HIV infection: adult versus children. In: Rotterdam H, Sommers SC, Racz P, Mayer PR, eds. Progress in AIDS pathology. New York: Field & Wood, 1989; 131-41.

26. Liberski PP, Yanagihara R, Gibbs CJ Jr, Gajdusek DC. Neuroaxonal dystrophy: an ultrastructural link between subacute spongiform virus encephalopathies and Alzheimer’s disease. In: Iqbal K, Wisniewski HM, Winblad B, eds. Alzheimer’s disease and related disorders. New York: Alan R Liss, 1989; 549-57.

27. Koh W, Schneck L, Cara J, Volk BW. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan’s disease). A review. Hum Pathol 1973; 4: 311-47.

28. Diedrich JF, Bendheim PE, Kim YS, Carp RI, Haase AT. Scrapie-associated prion protein accumulates in astrocytes during scrapie infection. Proc Natl Acad Sci USA 1991; 88: 375-9.

29. Diedrich JF, Minnigan H, Carp RI et al. Neuropathological changes in scrapie and Alzheimer’s disease are associated with increased expression of apolipoprotein E and cathepsin D in Astrocytes. J Virol 1991; 65: 4759-68.

30. Perlman S, Ries D. The astrocyte is a target cell in mice persistently infected with mouse hepatitis virus, strain JHM. Microb Pathogen 1987; 3: 309-14.

31. Matsushima Y, Ikemoto S. Genetic analysis of mouse tear protein: linkage of the Mtp-1 locus on chromosome 7. Jpn J Zootec Sci 1984; 55: 197-8 (in Japanese).

32. Otto J, von Deimling O. Pnt-4 and Pnt-5: new constituents of a gene cluster of chromosome 7 coding for esterproteases in the submandibular gland of the house mouse (Mus musculus). Biochem Genet 1981; 19: 431-44.

33. Hogarth PM, Walker ID, McKenzie IFC, Springer TA. The Ly-15 alloantigenic system: a genetically determined polymorphism of the murine lymphocyte function-associated antigen-1 molecule. Proc Natl Acad Sci USA 1989; 86: 526-30.

34. Davenport D, Martz E, Reynolds T, Kurzinger K, Springer TA. Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2.3 that participates in T lymphocyte-mediated killing. Proc Natl Acad Sci USA 1981; 78: 4535-9.

35. Sussman MA, Shubin RA, Kryuwa S, Stohlman SA. T-cell-mediated clearance of JHM virus from the central nervous system. J Virol 1989; 63: 3051-6.
36. Yamaguchi K, Goto N, Kyuwa S, Hayami M, Toyoda Y. Protection of mice from lethal coronavirus infection in the central nervous system by adoptive transfer of virus-specific T cell clones. J Neuroimmunol 1991; 32: 1-9.

37. Shubin RA, Sussman MA, Fleming JO, Stohlman SA. Relapsing encephalomyelitis following transfer of partial immunity to JHM virus. Microb Pathogen 1990; 8: 305-14.

38. Fujiwara K. Problems in checking inapparent infections in laboratory mouse colonies. An attempt at serological checking by anamnestic response. In: Scheneider HA, ed. Defining of the laboratory animals. Washington DC: Natl Acad Sci; 1974: 77-92.

39. Kyuwa S, Yamaguchi K, Hayami M, Hilgers J, Fujiwara K. Spontaneous production of interleukin-2 and interleukin-3 by spleen cells from mice infected with mouse hepatitis virus type 4. J Virol 1988; 62: 3506-9.